Skip to main content
. 2020 Dec 11;39(4):495–500. doi: 10.23876/j.krcp.20.107

Figure 2. Donor-derived, cell-free DNA (dd-cfDNA) cohorts in United States (US).

Figure 2

Cohorts of dd-cfDNA plasma number of samples from the US that were categorized as “low risk for rejection” (< 0.5%) and of indeterminate risk with 0.5% to 1.0% and > 1.0% categories during the course of coronavirus disease 2019 (COVID-19). The March-April nadir in total number of samples occurred prior to implementation of home remote phlebotomy.